Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 22.457 (Stand 01. November 2023)
Amgevita® (Adalimumab)202
Benepali® (Etanercept)1141
Cimzia® (Certolizumab)1019
Enbrel® (Etanercept)2872
Erelzi® (Etanercept)491
Flixabi® (Infliximab)10
Hulio® (Adalimumab)221
Humira® (Adalimumab)2908
Hyrimoz® (Adalimumab)193
Idacio® (Adalimumab)59
Imraldi® (Adalimumab)192
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)118
Kevzara® (Sarilumab)207
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)57
Olumiant® (Baricitinib)527
Orencia® (Abatacept)967
Remicade® (Infliximab)762
Remsima® (Infliximab)19
Rinvoq® (Upadacitinib)289
Rixathon® (Rituximab)20
RoActemra® (Tocilizumab)1371
Ruxience® (Rituximab)1
Simponi® (Golimumab)466
Xeljanz® (Tofacitinib)394
Yuflyma® (Adalimumab)15
Zessly® (Infliximab)2